Progressive supranuclear palsy (PSP) - Epidemiology Forecast-2032

January 2022 | 60 pages | ID: P2E54BE60359EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Progressive supranuclear palsy (PSP) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Progressive supranuclear palsy (PSP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Progressive supranuclear palsy (PSP) Understanding

The DelveInsight Progressive supranuclear palsy (PSP) epidemiology report gives a thorough understanding of the Progressive supranuclear palsy (PSP) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Progressive supranuclear palsy (PSP) in the US, Europe, and Japan. The report covers the detailed information of the Progressive supranuclear palsy (PSP) epidemiology scenario in seven major countries (US, EU5, and Japan).

Progressive supranuclear palsy (PSP) Epidemiology Perspective by DelveInsight

The Progressive supranuclear palsy (PSP) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Progressive supranuclear palsy (PSP) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Progressive supranuclear palsy (PSP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Progressive supranuclear palsy (PSP) Detailed Epidemiology Segmentation

The Progressive supranuclear palsy (PSP) epidemiology covered in the report provides historical as well as forecasted Progressive supranuclear palsy (PSP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Progressive supranuclear palsy (PSP) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Progressive supranuclear palsy (PSP) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Progressive supranuclear palsy (PSP) Epidemiology Report and Model provide an overview of the global trends of Progressive supranuclear palsy (PSP) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Progressive supranuclear palsy (PSP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Progressive supranuclear palsy (PSP)
• The report provides the segmentation of the Progressive supranuclear palsy (PSP) epidemiology

Report Highlights

• 11-year Forecast of Progressive supranuclear palsy (PSP) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Progressive supranuclear palsy (PSP)
• Cases of Progressive supranuclear palsy (PSP) by Mutation Types
• Progressive supranuclear palsy (PSP) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Progressive supranuclear palsy (PSP)?
• What are the key findings pertaining to the Progressive supranuclear palsy (PSP) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Progressive supranuclear palsy (PSP) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Progressive supranuclear palsy (PSP)?
• What are the currently available treatments of Progressive supranuclear palsy (PSP)?

Reasons to buy

The Progressive supranuclear palsy (PSP) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Progressive supranuclear palsy (PSP) market
• Quantify patient populations in the global Progressive supranuclear palsy (PSP) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Progressive supranuclear palsy (PSP) therapeutics in each of the markets covered
• Understand the magnitude of Progressive supranuclear palsy (PSP) population by its epidemiology
• The Progressive supranuclear palsy (PSP) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF PROGRESSIVE SUPRANUCLEAR PALSY (PSP)

3. PROGRESSIVE SUPRANUCLEAR PALSY (PSP): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Progressive supranuclear palsy (PSP) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Progressive supranuclear palsy (PSP) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Progressive supranuclear palsy (PSP) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Progressive supranuclear palsy (PSP) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Progressive supranuclear palsy (PSP) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Progressive supranuclear palsy (PSP) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Progressive supranuclear palsy (PSP) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Progressive supranuclear palsy (PSP) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Progressive supranuclear palsy (PSP) Treatment and Management
6.2. Progressive supranuclear palsy (PSP) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Progressive supranuclear palsy (PSP) Epidemiology in 7MM (2019-2032)
Table 2: Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Progressive supranuclear palsy (PSP) Epidemiology in the United States (2019-2032)
Table 4: Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Progressive supranuclear palsy (PSP) Epidemiology in Germany (2019-2032)
Table 6: Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Progressive supranuclear palsy (PSP) Epidemiology in France (2019-2032)
Table 8: Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Progressive supranuclear palsy (PSP) Epidemiology in Italy (2019-2032)
Table 10: Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Progressive supranuclear palsy (PSP) Epidemiology in Spain (2019-2032)
Table 12: Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Progressive supranuclear palsy (PSP) Epidemiology in the United Kingdom (2019-2032)
Table 14: Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Progressive supranuclear palsy (PSP) Epidemiology in Japan (2019-2032)
Table 16: Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Progressive supranuclear palsy (PSP) Epidemiology in 7MM (2019-2032)
Figure 2 Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Progressive supranuclear palsy (PSP) Epidemiology in the United States (2019-2032)
Figure 4 Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Progressive supranuclear palsy (PSP) Epidemiology in Germany (2019-2032)
Figure 6 Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Progressive supranuclear palsy (PSP) Epidemiology in France (2019-2032)
Figure 8 Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Progressive supranuclear palsy (PSP) Epidemiology in Italy (2019-2032)
Figure 10 Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Progressive supranuclear palsy (PSP) Epidemiology in Spain (2019-2032)
Figure 12 Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Progressive supranuclear palsy (PSP) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Progressive supranuclear palsy (PSP) Epidemiology in Japan (2019-2032)
Figure 16 Progressive supranuclear palsy (PSP) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report